Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age19+
SponsorSeoul National University Hospital
About this trial
Prospective observational study of trastuzumab emtansine immediately after trastuzumab deruxtecan in patients with advanced HER2-positive breast cancer in Korea
Eligibility criteria
Qualifiers
HER2-positive, advanced (unresectable locally advanced or metastatic) breast cancer
Prior treatment with trastuzumab deruxtecan(T-DXd) in the advanced setting
Intention to treat with Trastuzumab Emtansine (T-DM1) as first therapy upon T-DXd progression
Disqualifiers
Any systemic treatment, other than T-DM1, for breast cancer after trastuzumab deruxtecan (As an exception, patients treated with endocrine agents, not in combination with cytotoxics or antibody-drug conjugates, will be permitted in the study)
Has been previously treated with T-DM1 for advanced breast cancer
Has been previously treated with 4 or more lines of therapy for advanced breast cancer
Half (50%) or more patients will be those who were treated with second-line trastuzumab deruxtecan (i.e. patients at the later line will be capped).
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov